OncLive

Phase 2 Study of Telisotuzumab Adizutecan in ctDNA-Positive CRC Could Expand Treatment Beyond Active Surveillance | OncLive Kanwal P.S. Raghav, MBBS, MD, discusses a phase 2 study evaluating the MET-directed ADC Temab-A vs SOC active surveillance in post-adjuvant, ctDNA-positive CRC.

📖A new phase 2 trial is evaluating the MET-directed ADC telisotuzumab adizutecan vs active surveillance in patients with CRC with detectable ctDNA after adjuvant therapy. @mdanderson.bsky.social #oncology #CRC
👉Read more: www.onclive.com/view/phase-2...

Giredestrant Plus Palbociclib Misses PFS End Point in ER+/HER2– Advanced Breast Cancer | OncLive Giredestrant plus palbociclib did not yield a statistically significant PFS improvement in ER-positive/HER2-negative locally advanced or metastatic breast cancer.

📊 Giredestrant + Palbociclib Misses PFS End Point in ER+/HER2– Advanced Breast Cancer #BreastCancer #bcsm #ClinicalTrials #Oncology #CancerResearch
🔗 Read more: www.onclive.com/view/giredes...

The Front Line of Lung Cancer Diagnosis: How Interventional Pulmonology Drives Early Detection, Staging, and Treatment Planning | OncLive Jasleen Pannu, MBBS, explains how interventional pulmonologists guide timely molecular testing and treatment through lung cancer diagnosis, staging, and tissue acquisition.

Between diagnosis, staging, and treatment planning, pulmonologists play a key role in lung cancer management. Jasleen Pannu, MBBS, of Ohio State University Wexner Medical Center, explains how these specialists fit into the multidisciplinary equation #lcsm #oncology www.onclive.com/view/the-fro...

Another highlight from #MBCC26: Sara Nunnery, MD's conversation with Neil Iyengar, MD, for the upcoming Breast Cancer Briefing podcast! Can't wait for the series to launch? Neither can we. In the meantime, check out our other #bcsm coverage from the meeting! #Oncology
www.onclive.com/conference/m...

We had a blast at last night's closing reception for #MBCC26! What a fantastic way to end another successful year of sharing breast #oncology insights under the beautiful Miami sky. Until next year! #bcsm

It's always great to speak with @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, who sat down with us at #MBCC26 to highlight considerations across the realm of metastatic breast cancer management! See our site for this conversation and more. #bcsm #oncology
www.onclive.com/conference/m...

A huge thanks to Meghan R. Flanagan, MD, MPH, of @fredhutch.org, for stopping by during #MBCC26 to talk all things breast surgical oncology! Head to our site for exclusive commentary from Dr Flanagan and more. #bcsm #oncology
www.onclive.com/conference/m...

Dr Kalinsky on Multidisciplinary Considerations for ESR1+ Breast Cancer Care | OncLive Kevin Kalinsky, MD, MS, FASCO, notes insights from a molecular tumor board discussion about the optimal management of HR-positive metastatic breast cancer.

WATCH: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, notes insights from a molecular tumor board discussion about the optimal management of HR-positive metastatic breast cancer. #MBCC26 #bcsm #oncology
www.onclive.com/view/dr-kali...

Dr Flanagan on the Importance of Multidisciplinary Breast Cancer Tumor Boards | OncLive Meghan R. Flanagan, MD, MPH, noted the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies.

WATCH: Meghan R. Flanagan, MD, MPH, of @fredhutch.org, notes the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies. #MBCC26 #bcsm #Oncology
www.onclive.com/view/dr-flan...

Jakel on a Multidisciplinary Discussion About Individualized Breast Cancer Management | OncLive Patricia Jakel, MSN, notes the factors that influence breast cancer care, as exemplified in a discussion at the 43rd Annual Miami Breast Cancer Conference.

WATCH: Patricia Jakel, MSN, notes the factors that influence breast cancer care, as exemplified in a discussion at the 43rd Annual Miami Breast Cancer Conference. #mbcc26 #bcsm #Oncology
www.onclive.com/view/jakel-o...

The last presentations of #MBCC2026 are in full swing! The conference may be wrapping up, but there is more coverage to come, so check back on our site as we continue to report on insights you can "use on Monday"! #bcsm #oncology
www.onclive.com/conference/m...

Watch Sara Nunnery, MD, MSCI, sit down with Kelly McCann, MD, PhD, to preview the launch of the Breast Cancer Briefing podcast series! They filmed the episode on the ground at #MBCC2026. While you're waiting for the premiere, check out our conference insights. #bcsm
www.onclive.com/conference/m...

Zovegalisib Plus Fulvestrant Yields Durable Efficacy in PIK3CA+, HR+/HER2– Advanced Breast Cancer | OncLive Zovegalisib plus fulvestrant drove responses in HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer

Zovegalisib Plus Fulvestrant Yields Durable Efficacy in PIK3CA+, HR+/HER2– Advanced Breast Cancer

#MBCC2026 #bcsm #oncology

www.onclive.com/view/zovegal...

We are LIVE on the first day of the Breast Cancer Briefing podcast filmings, which are happening at #MBCC2026! Check out our X livestream now until noon to catch a peek at one of our first episodes, where Sara Nunnery, MD, is chatting with Irene Kang, MD, about TNBC! #bcsm #oncology

The sun is shining for Day 3 of #MBCC2026! Follow along to see which expert insights we hear today, and as always, see our site for additional exclusive commentary and coverage! #bcsm #oncology
www.onclive.com/conference/m...

Rodich on How Oncologists Can Discuss Integrative Medicine for Breast Cancer | OncLive Lillian Rodich, MSPAS, MPH, highlights ways that medical oncologists can counsel patients with breast cancer about integrative medicine modalities.

WATCH: Lillian Rodich, MSPAS, MPH, highlights ways that medical oncologists can counsel patients with breast cancer about integrative medicine modalities. @mskcancercenter.bsky.social #MBCC2026 #bcsm #oncology
www.onclive.com/view/rodich-...

FDA Approves Pylarify TruVu for PSMA-PET Imaging in Prostate Cancer | OncLive The FDA has cleared Pylarify TruVu injection, a new formulation of its F 18 PSMA imaging agent for prostate cancer.

🚨 #BREAKING 🚨: The @fda.gov has approved Pylarify TruVu (piflufolastat F 18) injection for PET imaging of PSMA+ lesions in men with prostate cancer.

Learn more about the decision: www.onclive.com/view/fda-app...

AI-Driven Digital Pathology May Refine Treatment Selection in HR+ Early Breast Cancer | OncLive W. Fraser Symmans, MD, discusses data on the current state of AI-driven digital pathology in HR+ breast cancer.

AI-Driven Digital Pathology May Refine Treatment Selection in HR+ Early Breast Cancer

#AI #bcsm #oncology #MBCC2026

www.onclive.com/view/ai-driv...

Check out this cozy setup, which is all ready for tomorrow's LIVE premiere of the Breast Cancer Briefing podcast series, hosted by Sara Nunnery, MD! We'll be filming throughout the day right on the #MBCC2026 conference floor. Stop by to get an exclusive peek! #bcsm
www.onclive.com/conference/m...

Thanks so much to Pattie Jakel for stopping by during #MBCC2026 to provide an in-depth preview of the oncology nursing conversations happening at the meeting! Mark your calendars for the nursing track tomorrow, & see our site for more from the meeting! #bcsm #oncology
www.onclive.com/conference/m...

ctDNA in Early-Stage Breast Cancer: Prognostic Power vs Clinical Actionability | OncLive Heather A. Parsons, MD, MPH, shares growing evidence for the prognostic value of circulating tumor DNA in early-stage breast cancer.

Is ctDNA ready for primetime in early-stage breast cancer? Heather A. Parsons, MD, MPH, breaks down what's known regarding the prognostic value of ctDNA and how this biomarker could affect clinical practice #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/ctdna-i...

Real-World Analysis Highlights Tolerability of T-DXd in HER2-Low Metastatic Breast Cancer Treated in a Community Setting | OncLive T-DXd was associated with low rates of real-world discontinuation in HER2-low metastatic breast cancer.

A real-world analysis showed T-DXd led to toxicity-related discontinuation at rates similar to those from the DESTINY-Breast04 trial in patients with metastatic HER2-low breast cancer treated in the community setting #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/real-wo...

We are gearing up for day 2 of #MBCC2026! Stay tuned for live updates from the meeting and our exclusive coverage of expert insights, debates, and more! #bcsm #oncology
www.onclive.com/conference/m...

Evidence Elevates TROP2-Directed ADCs Over Chemotherapy in First-Line Metastatic TNBC | OncLive Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.

With TROP2-Directed ADCs set to redefine first-in e TNBC management, Ana C. Garrido-Castro, MD, of @danafarber.bsky.social, broke down the pivotal trials and data that could alter standards of care #bcsm #oncology www.onclive.com/view/evidenc...

Rugo Spotlights Multidisciplinary Insights of Interest at the 43rd Annual Miami Breast Cancer Conference | OncLive Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

The 43rd Annual Miami Breast Cancer Conference is underway. To help you prepare, @hoperugo.bsky.social sat down with OncLive to preview some of the top sessions, talks, and workshops headlining this year's meeting #gotoPER #MBCC26 #bcsm #oncology www.onclive.com/view/rugo-sp...

This morning's Women in Oncology event was a stunning success! Check out these behind-the-scenes vignettes, and follow along as we share more footage from the morning, as well as exclusive insights from the speakers! #bcsm #oncology

Dr Galsky on the Background of the KEYNOTE-B15 Trial in MIBC | OncLive Matthew D. Galsky, MD, discusses the background of the phase 3 KEYNOTE-B15 trial in muscle-invasive bladder cancer.

📹 Watch Matthew D. Galsky, MD, of @mountsinainyc.bsky.social, shed light on the background of the phase 3 KEYNOTE-B15 trial in muscle-invasive bladder cancer. @ascocancer.bsky.social #GU26 #oncology #MIBC

www.onclive.com/view/dr-gals...

We have touched down in Sunny Miami, Florida, for the 43rd Annual Miami Breast Cancer Conference! We are having a blast catching up with so many familiar faces. Check back to see what we've been up to while the meeting's been kicking off! #MBCC2026 #bcsm #oncology
www.onclive.com/conference/m...

During CRC Awareness Month, John Marshall, MD, and Christopher Lieu, MD, explore potential drivers of the incidence rise in young adults and the multidisciplinary efforts required to better manage patients with this disease. #CRC
🔐Access their full insights below!
www.onclive.com/view/rising-...

🚨BREAKING🚨: The @fda.gov has approved teclistamab plus subcutaneous daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy. #mmsm #hematology
www.onclive.com/view/fda-app...